Experts question whether regular boosting is a sustainable strategy to manage the coronavirus long-term. Deepta Bhattacharya, PhD, professor of immunobiology at the College of Medicine – Tucson, is quoted.

U.S. colleges and universities have relaxed campus requirements for coronavirus testing of vaccinated people in recent weeks, chipping away at some of the last widespread surveillance testing programs and dismaying public health experts, who say that robust sources of transmission data will be lost. Saskia Popescu, PhD, infectious disease epidemiologist and infection prevention expert at the Mel and Enid Zuckerman College of Public Health, is quoted.

The U.S. could soon be living with daylight saving time year-round. Sleep experts say there are drawbacks to that plan and the alternatives. Denise Rodriguez Esquivel, PhD, an assistant professor of psychiatry at the College of Medicine – Tucson who specializes in the treatment of insomnia and circadian-rhythm disorders, is quoted.

A doctoral student is using the Infection and Inflammation as Drivers of Aging training program to investigate menopause-onset asthma.

Dr. Randy Horwitz will share integrative medicine approaches to treating chronic inflammation and educate participants about healing-oriented medicine.

Collaboration among many parties enabled the Phoenix Bioscience Core to become a reality. Guy Reed, MD, MS, dean of the UArizona College of Medicine – Phoenix, is quoted.

“A Look Back: Reflections on Medical History & Artifacts from the Pages of The American Journal of Gastroenterology” is a new book about medical artifacts written by Robert E. Kravetz, MD, FACP, MACG, a College of Medicine – Phoenix associate clinical professor of internal medicine.

When COVID-19 vaccines first became available, Native Americans acted swiftly and with determination to get their shots. Yet, tribal health officials said, they eventually ran up against the challenges that broadly stalled the U.S. vaccination campaign.

Rucaparib monotherapy significantly extended progression-free survival compared with placebo as first-line maintenance treatment for women with ovarian cancer, according to data from a phase 3 clinical trial.